In the era of precision medicine, it is crucial to identify molecular alterations that will guide
the therapeutic management of patients. In this context, circulating tumoral DNA (ctDNA) …

Tissue biopsy is the standard diagnostic procedure for cancers and also provides a material
for genotyping, which can assist in the targeted therapies of cancers. However, tissue biopsy …

Over the past decade, advances in molecular biology and genomics techniques have
revolutionized the diagnosis and treatment of cancer. The technological advances in tissue …

BACKGROUND: Cell-free DNA (CFDNA) in the plasma/serum of patients with cancer
demonstrates tumour-associated genetic alterations, offering possibilities for diagnosis …

Advancements in the clinical practice of non-small cell lung cancer (NSCLC) are shifting
treatment paradigms towards increasingly personalized approaches. Liquid biopsies using …

Cell-free DNA (cfDNA) analysis represents a promising method for the diagnosis, treatment
selection and clinical follow-up of cancer patients. Although its general methodological …

Circulating tumor DNA (ctDNA) is a component of cell-free DNA that is shed by malignant
tumors into the bloodstream and other bodily fluids. Levels of ctDNA are typically low …

The development of new circulating-tumor DNA (ctDNA) analysis techniques has led to an
explosion of studies demonstrating exciting clinical applications. Non-invasive genotyping …

Molecular analyses of circulating tumor DNA (ctDNA) in plasma from cancer patients have
the potential to deliver minimally invasive diagnostic and disease-monitoring biomarkers …

BACKGROUND Targeted therapies have markedly changed the treatment of cancer over
the past 10 years. However, almost all tumors acquire resistance to systemic treatment as a …